Poster: AACR (American Association for Cancer Research), April 5-10, 2024, San Diego CA
A systemically delivered, clinically-ready, attenuated Salmonella Typhimurium strain ACTM-838 alters the tumor microenvironment and provides durable anti-tumor activity in vivo VIEW POSTER PDF
This article is featured on another website.
Mytrelle at Meeting on the Mesa
Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease at the 2025 Cell & Gene Meeting on the Mesa
Mytrelle at Meeting on the Mesa
Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease at the 2025 Cell & Gene Meeting on the Mesa
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.